Investor Relations Captor Therapeutics ®
Progress in research and development related to CT-01 project
Current Report No: 31/2022
Date of preparation:
Subject: Progress in research and development related to CT-01 project
Legal basis: Art. 17(1) of MAR – inside information
The Management Board of Captor Therapeutics S.A., with its registered office in Wroclaw (the "Company"), informs about the nomination of the candidate drug CPT-6281 in the CT-01 project and commencement of CTA/IND-enabling studies.
As a results of candidate drug nomination, the Company has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization (CDMO), this being the first in a series of IND-enabling studies that will allow entering to the clinical phase next year.
The Company will inform about further progress in CT-01 project in accordance with legal requirements.